My Colorectal Cancer tumor markers are rising — what does this mean

Rising Tumor Markers in Colorectal Cancer: What This Means

I understand this is concerning. Let me help you understand what rising tumor markers typically indicate and what your care team should be evaluating.

What Rising Tumor Markers Generally Mean

Carcinoembryonic Antigen (CEA) is the most common tumor marker monitored in colorectal cancer. When CEA levels rise after treatment or surgery, it can signal several possibilities:

• Potential recurrence: Cancer cells may be returning or spreading
• Residual disease: Cancer cells that weren't completely removed during surgery
• False positive: About half of CEA elevations after surgery are actually false alarms—especially single high readings or values between 5-15 ng/mL

According to NCCN Guidelines for Colon Cancer, approximately half of CEA elevations after complete surgical removal are false positives, with most being isolated high readings. However, results above 35 ng/mL are more likely to represent true recurrence.

How Doctors Typically Respond to Rising Markers

When CEA rises, your oncology team should follow a systematic evaluation approach:

Standard workup includes:

• Colonoscopy (to check the colon directly)
• CT scans of chest, abdomen, and pelvis
• Physical examination
• Consideration of PET/CT scan if other imaging is normal but CEA continues rising

Repeat testing: If initial imaging is normal but CEA keeps rising, NCCN Guidelines recommend repeating CT scans every 3 months until either disease is identified or the CEA level stabilizes or declines.

Important Context About Sensitivity and Specificity

The NCCN Guidelines note that CEA testing has:

• Sensitivity of 68% (meaning it catches about 2 out of 3 actual recurrences)
• Specificity of 97% (meaning it correctly identifies non-cancer cases most of the time)

This means rising CEA is helpful but not perfect—some recurrences won't show up on CEA, and some rises are false alarms.

Emerging Tests That May Help

Recent advances in molecular residual disease (MRD) testing using circulating tumor DNA (ctDNA) from blood samples show promise. According to NCCN Guidelines, studies have found:

• ctDNA detected after surgery is associated with 7 times higher risk of recurrence
• ctDNA detected after chemotherapy is associated with 17 times higher risk of recurrence

These blood-based tests may provide earlier detection of recurrence than traditional imaging, though they're still being studied for routine clinical use.

Questions to Ask Your Oncology Team

Since rising markers require personalized evaluation, ask your doctor:

1. What is my specific CEA level, and how much has it risen? (This helps determine urgency—small rises may be monitored, while significant rises warrant immediate workup)

2. What imaging studies do you recommend, and in what timeframe? (Your doctor may recommend CT, PET/CT, or colonoscopy based on your specific situation)

3. Should we consider ctDNA or other molecular testing to help clarify whether this represents true recurrence?

4. What is your plan if imaging is normal but CEA continues rising? (This helps you understand the surveillance strategy)

5. Are there any treatment options available if recurrence is confirmed? (This is important because early detection is only helpful if treatment options exist)

Why This Matters

According to NCCN Guidelines, the key principle is that early detection of recurrence through tumor markers is only beneficial if you have therapeutic options that could potentially treat the disease. Your care team needs to balance thorough evaluation with avoiding unnecessary procedures.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources cited:

• NCCN Guidelines for Colon Cancer (Version 5.2025) - CEA monitoring and management protocols
• NCCN Guidelines for Colon Cancer - Circulating tumor DNA (ctDNA) as prognostic marker